Edition:
United Kingdom

Oxford Immunotec Global PLC (OXFD.OQ)

OXFD.OQ on NASDAQ Stock Exchange Global Market

11.91USD
16 Feb 2018
Change (% chg)

$0.05 (+0.42%)
Prev Close
$11.86
Open
$11.87
Day's High
$12.16
Day's Low
$11.84
Volume
34,093
Avg. Vol
46,544
52-wk High
$19.50
52-wk Low
$10.26

Chart for

About

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company's product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and... (more)

Overall

Beta: -0.09
Market Cap(Mil.): $427.87
Shares Outstanding(Mil.): 25.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 148.59 16.64
EPS (TTM): -- -- --
ROI: -- 9.38 10.66
ROE: -- 14.72 14.30

BRIEF-James Flynn Reports 5.1 Pct Passive Stake In Oxford Immunotec Global Plc As Of Jan 22

* JAMES FLYNN REPORTS 5.1 PERCENT PASSIVE STAKE IN OXFORD IMMUNOTEC GLOBAL PLC AS OF JANUARY 22 - SEC FILING Source text: [http://bit.ly/2BNPx1n] Further company coverage:

01 Feb 2018

BRIEF-Oxford Immunotec Announces Preliminary Revenue For Q4

* FY2017 REVENUE VIEW $104.1 MILLION -- THOMSON REUTERS I/B/E/S

08 Jan 2018

BRIEF-Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit

* OXFORD IMMUNOTEC GLOBAL - CO, QIAGEN REACHED A SETTLEMENT IN LAWSUIT IN U.S. COURT ALLEGING PATENT INFRINGEMENT IN RELATION TO QIAGEN'S PRODUCTS

15 Dec 2017

BRIEF-Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech AB​

* Oxford Immunotec Global Plc - ‍on Nov 17, unit entered into a second amendment to purchase agreement with Mabtech AB​

21 Nov 2017

BRIEF-Oxford Immunotec Global Q3 loss per share $0.70

* Oxford Immunotec reports third quarter 2017 financial results

31 Oct 2017

BRIEF-Oxford Immunotec announces update in patent infringement litigation

* Oxford Immunotec announces update in patent infringement litigation

27 Sep 2017

BRIEF-Oxford Immunotec updates on amendment to supply agreement with StemCell Technologies ​

* Oxford Immunotec Global PLC - ‍on Sept 1 unit entered into second amendment to supply agreement with StemCell Technologies Canada f/k/a StemCell Technologies ​

06 Sep 2017

BRIEF-Oxford Immunotec appoints Stefan Linn as COO

* Oxford Immunotec appoints Stefan Linn as chief operating officer Source text for Eikon: Further company coverage:

30 Aug 2017

Competitors

  Price Chg
Thermo Fisher Scientific Inc. (TMO.N) $210.61 -0.11
Bruker Corporation (BRKR.OQ) $32.10 -0.20
STERIS Corp (STE.N) $90.11 +0.62

Earnings vs. Estimates